$57.35
9.20% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US74006W1080
Symbol
PRAX

Praxis Precision Medicines Inc Stock price

$57.35
+16.90 41.78% 1M
+27.68 93.29% 6M
-19.61 25.48% YTD
-14.70 20.40% 1Y
+31.70 123.59% 3Y
-227.65 79.88% 5Y
-227.65 79.88% 10Y
-227.65 79.88% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+4.83 9.20%
ISIN
US74006W1080
Symbol
PRAX
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$905.9m
Net debt
positive
Cash
$301.3m
Shares outstanding
21.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
155.4 | 12,910.7
EV/Sales
116.6 | 9,688.5
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
92.2%
Return on Equity
-41.0%
ROCE
-67.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.8m | $93.5k
EBITDA
$-271.4m | $-299.1m
EBIT
$-271.6m | $-307.7m
Net Income
$-251.0m | $-286.9m
Free Cash Flow
$-191.4m
Growth (TTM | estimate)
Revenue
339.0% | -98.9%
EBITDA
-105.2% | -49.7%
EBIT
-104.7% | -53.7%
Net Income
-102.9% | -56.9%
Free Cash Flow
-101.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,494.6% | -319,893.1%
EBIT
-3,497.6%
Net
-3,232.6% | -306,796.1%
Free Cash Flow
-2,464.4%
More
EPS
$-11.7
FCF per Share
$-9.1
Short interest
12.6%
Employees
116
Rev per Employee
$70.0k
Show more

Is Praxis Precision Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Praxis Precision Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Praxis Precision Medicines Inc forecast:

18x Buy
90%
1x Hold
5%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a Praxis Precision Medicines Inc forecast:

Buy
90%
Hold
5%
Sell
5%

Financial data from Praxis Precision Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
7.77 7.77
339% 339%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 57 57
29% 29%
738%
- Research and Development Expense 222 222
147% 147%
2,857%
-271 -271
105% 105%
-3,492%
- Depreciation and Amortization 0.23 0.23
48% 48%
3%
EBIT (Operating Income) EBIT -272 -272
105% 105%
-3,495%
Net Profit -251 -251
103% 103%
-3,231%

In millions USD.

Don't miss a Thing! We will send you all news about Praxis Precision Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Praxis Precision Medicines Inc Stock News

Neutral
GlobeNewsWire
14 days ago
BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on October 1, 2025, the Compensation Committee of Praxis' Board of Directors ...
Neutral
Business Wire
17 days ago
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the close of over $29 million in additional financing. The company also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) and a new research collaboration w...
Neutral
GlobeNewsWire
about one month ago
Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Praxis (PRAX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in  Praxis and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
More Praxis Precision Medicines Inc News

Company Profile

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marcio Souza
Employees 116
Founded 2015
Website praxismedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today